News

E-Scape Bio, the Gladstone Institutes’ spin-off company working to develop therapies for neurodegenerative disorders such as Alzheimer’s disease, announced that it has raised a total of $63 million in Series A financing from investors. The biotech startup is developing small-molecule drugs that target apoE4, a gene thought to increase the risk…

Prof. Shi-Jiang Li, PhD, is the recipient of the 2017 Alzheimer Award granted every year by the associate editors of the Journal of Alzheimer’s Disease (JAD). Li was singled out for his and his team’s outstanding work published in the journal about a new index called the “characterizing Alzheimer’s…

Researchers fed the antioxidant fisetin, found in strawberries and other fruits and vegetables, to mice for seven months and found that the compound partially protected the animals from age-associated cognitive decline. Fisetin’s effects correlated with the restoration of neuronal function and less brain inflammation. The results, which follows previous work with…

New results from its intepirdine (RVT-101) and nelotanserin research programs on Alzheimer’s disease (AD) and Lewy body dementia will be shared soon, Axovant Sciences announced. The data will be presented at the 2017 Alzheimer’s Association International Conference (AAIC) in London  July 16-20. Intepirdine is a selective antagonist of the…

People at risk for Alzheimer’s disease who spend more time doing moderate-intensity exercise have a healthier level of glucose metabolism in the brain — considered a reflection of how healthy and active the brain really is. In contrast, low-intensity physical activity, such as a slow walk, was not related to brain…

Patients with Alzheimer’s disease who experience delusions and hallucinations are five times more likely to be misdiagnosed than Alzheimer’s patients without psychosis, new research from St. Michael’s Hospital in Toronto, Canada, found. The study, “Determining the impact of…

AgeneBio has received a $750,000 grant from the Alzheimer’s Drug Discovery Foundation (ADDF) to support the development of a novel GABAA discovery program targeting hippocampal overactivity in the brain, which is thought to contribute to neurodegeneration and cognitive decline in Alzheimer’s disease (AD) patients. AgeneBio’s pipeline of therapies is…

An enzyme called asparagine endopeptidase contributes to Parkinson’s as well as Alzheimer’s by slicing off fragments of proteins that end up being toxic, a study reports. Previous researched showed that the enzyme, also known as AEP, plays a role in Alzheimer’s. The new study indicates it plays a role in Parkinson’s,…

William Glass, who has seen the devastating toll that Alzheimer’s disease inflicts on families as a caregiver for his mother, is setting out on a 640-mile walk from Atlanta to Washington, D.C., to raise awareness of the disease and advocate for Congress to increase funding for research. The Chicago native…

Patients with dementia or other neurodegenerative diseases may die earlier if family members who act as caregivers have poor mental health, according to a study published recently in the Proceedings of the National Academy of Sciences (PNAS). While depression and anxiety among caregivers has been linked to a poorer…